After this breakthrough, which revealed the anti-tumor potential of immune checkpoint blockade, hallmark clinical trials resulted in development of the anti-CTLA-4 monoclonal antibody, Ipilimumab, which was approved for treatment of melanoma in 2011 [42,43,44]. Here, CTLA4 is linked to melanoma.